The position of Health Canada on the substitution of biological products (biosimilars are called "subsequent-entry" products in Canada) is clear but rather soft: "Health Canada does not support the automatic substitution of a subsequent-entry biologic for its reference biologic drug.
16, 20, 21 Similarly, although some have highlighted the fact that subsequent entry biologics' effectiveness may differ from that of their reference biologics, they are also generally considered to be as effective.
Sometimes, critical interventions such as peripheral intravenous (IV) placement must be deferred until a subsequent entry into the high-risk area.
And in a subsequent entry describing the Brown-Wilson encounter, McElroy describes Brown as a "big kid" who "started running right at the cop" and "wouldn't stop" even after the first three gunshots.
A subsequent entry dismisses a hostile review of Civilization by another critic, Alex von Tunzelmann.
They are called follow-on biologics (FOB) in the US, subsequent-entry biologics (SEB) in Canada, and follow-on proteins (FOP) in Japan.
As those of us within the Type 1 diabetes community know, and as a subsequent Snopes entry clarified, "Walmart" insulin is an older form, one that few Type 1 diabetics use.
With a goal of further understanding the use of biologic therapies in RA treatment, objectives of this study were to describe patterns of biologic utilization among commercially insured patients with RA, to compare utilization patterns of anti-TNF agents used as a first versus as a subsequent biologic agent, and to compare real-world dosing patterns with label recommendations.
The mean dosing interval was shorter for patients with infliximab as a subsequent-line biologic than for those who used it first-line and in both settings the average interval was shorter than the label recommendation.
A linear probability model (LPM) was used to test whether there was a statistically significant effect for the experimental scenario on individual purchase decisions, as well as the subsequent entry of the company into the market.
The likelihood of responding to a subsequent biologic treatment decreased as the number of previous treatments with TNF-α inhibitors increased for six of the seven response criteria examined.
